Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/46875
Title: | The impact of hypo-attenuated leaflet thickening on haemodynamic valve deterioration following transcatheter aortic valve replacement. | Authors: | Rashid H.N.;Michail M.;Ramnarain J.;Nasis A. ;Nicholls S.J.;Cameron J.D.;Gooley R.P. | Monash Health Department(s): | Cardiology (MonashHeart) Respiratory and Sleep Medicine |
Institution: | (Rashid, Ramnarain, Nasis, Nicholls, Cameron, Gooley) Monash Heart, Monash Health and Monash Cardiovascular Research Centre, Monash University, Australia (Michail) Sussex Cardiac Centre, University Hospital Sussex NHS Trust, Brighton, United Kingdom |
Issue Date: | 6-Mar-2022 | Publisher: | Elsevier Inc. | Place of publication: | United States | Publication information: | Journal of Cardiovascular Computed Tomography. 16(2) (pp 168-173), 2022. Date of Publication: 01 Mar 2022. | Journal: | Journal of Cardiovascular Computed Tomography | Abstract: | Background: Hypo-attenuated leaflet thickening (HALT) may occur following transcatheter aortic valve replacement (TAVR), however, it remains unclear if HALT is a predictor of haemodynamic valve deterioration (HVD). Aim(s): To determine the impact of HALT on the occurrence of HVD. Method(s): We prospectively evaluated 186 patients for the presence of HALT at a median of 6 weeks following TAVR (Interquartile-range [IQR] 4-12 weeks). HALT depth and area were measured. HVD encompassed any of the following: mean gradient >=20 mmHg with an increase in gradient >=10 mmHg from baseline, Doppler velocity index reduction >=0.1 or new moderate-to-severe valvular regurgitation. Routine echocardiograms at discharge, one month and annually, were assessed by echo-cardiologists that were blinded to the HALT status. Result(s): LT prevalence was 17.7% (33/186). HVD was present in 8.6% (16/186) at a median follow-up of 2 years (IQR 1-3); two required valve re-intervention and five required anticoagulation. HALT was the only independent predictor of HVD on multivariate analysis (OR 33.3, 95%CI 7.4-125). Patients with HALT were more likely to develop HVD, require repeat valve intervention and have higher trans-valvular gradients at up to 3-year follow-up. Patients with HALT had a median cumulative thickness of 2.9 mm (IQR 1.9-4.7) and area of 64.2 mm2 (IQR 40.9-91.6). Thresholds for HALT in predicting HVD were a cumulative depth of 2.4 mm (Specificity 94.1%, Sensitivity 75.0%, AUC = 0.87) and cumulative area of 28 mm2 (Specificity 92.2%, Sensitivity 81.3%, AUC = 0.86). Conclusion(s): HALT is an independent predictor of HVD, which exhibits specific depth and area thresholds to predict HVD. CT following TAVR may determine patients at risk of HVD.Copyright © 2021 | DOI: | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1016/j.jcct.2021.11.013 | PubMed URL: | 34852974 [https://www.ncbi.nlm.nih.gov/pubmed/?term=34852974] | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/46875 | Type: | Article | Subjects: | aged anticoagulant therapy body mass cerebrovascular accident chronic obstructive lung disease computer assisted tomography coronary artery bypass graft echocardiography four dimensional computed tomography heart cycle heart failure percutaneous coronary intervention practice guideline surface property transcatheter aortic valve implantation transient ischemic attack valve deterioration/co acetylsalicylic acid/pv [Special Situation for Pharmacovigilance] clopidogrel/pv [Special Situation for Pharmacovigilance] heparin/ia [Intraarterial Drug Administration] heparin/pv [Special Situation for Pharmacovigilance] iohexol/pv [Special Situation for Pharmacovigilance] protamine/pv [Special Situation for Pharmacovigilance] aortic valve prosthesis computed tomography scanner heart valve bioprosthesis percutaneous aortic valve percutaneous aortic valve bioprosthesis haemodynamic valve deterioration/co hypoattenuated leaflet thickening/co CoreValve/Evolut |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.